These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 18442879)

  • 21. [Case of schizophrenia in which depressive and negative symptoms relapsed on switching from oral risperidone to risperidone long-acting injection].
    Mori T
    Seishin Shinkeigaku Zasshi; 2011; 113(10):977-82. PubMed ID: 22187885
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diffusion of a new drug: a comparative analysis of adoption, treatment complexity, and persistence of risperidone long-acting injectable therapy in the Netherlands.
    Pechlivanoglou P; Vehof J; van Agthoven M; de Jong-van den Berg LT; Postma MJ
    Clin Ther; 2010 Jan; 32(1):108-18. PubMed ID: 20171417
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of treatment response in second-episode versus first-episode schizophrenia.
    Emsley R; Oosthuizen P; Koen L; Niehaus D; Martinez L
    J Clin Psychopharmacol; 2013 Feb; 33(1):80-3. PubMed ID: 23277247
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Switching to long-acting injectable risperidone is beneficial with regard to clinical outcomes, regardless of previous conventional medication in patients with schizophrenia.
    Marinis TD; Saleem PT; Glue P; Arnoldussen WJ; Teijeiro R; Lex A; Latif MA; Medori R
    Pharmacopsychiatry; 2007 Nov; 40(6):257-63. PubMed ID: 18030649
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Long-acting injectable risperidone: naturalistic study in three hospitals in Aquitaine].
    Raignoux C; Dusouchet T; Bret P; Queuille E; Biscay ML; Caron J; Bret MC
    Encephale; 2007 Dec; 33(6):973-81. PubMed ID: 18789790
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Experience with injectable long-acting risperidone in long-term therapy after an acute episode of schizophrenia: the SPHERE Study.
    De la Gándara J; San Molina L; Rubio G; Rodriguez-Morales A; Hidalgo Borrajo R; Burón JA
    Expert Rev Neurother; 2009 Oct; 9(10):1463-74. PubMed ID: 19831836
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment compliance in veterans administration schizophrenia spectrum patients treated with risperidone long-acting injectable.
    Duncan EJ; Woolson SL; Hamer RM
    Int Clin Psychopharmacol; 2012 Sep; 27(5):283-90. PubMed ID: 22644368
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The cost-effectiveness of risperidone long-acting injection in the treatment of schizophrenia.
    Chue P; Chue J
    Expert Rev Pharmacoecon Outcomes Res; 2012 Jun; 12(3):259-69. PubMed ID: 22812548
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A long-term prospective study on the outcome of bipolar patients treated with long-acting injectable risperidone.
    Vieta E; Nieto E; Autet A; Rosa AR; Goikolea JM; Cruz N; Bonet P
    World J Biol Psychiatry; 2008; 9(3):219-24. PubMed ID: 18609430
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Challenges in the design and conduct of controlled clinical effectiveness trials in schizophrenia.
    Rosenheck RA; Krystal JH; Lew R; Barnett PG; Thwin SS; Fiore L; Valley D; Huang GD; Neal C; Vertrees JE; Liang MH;
    Clin Trials; 2011 Apr; 8(2):196-204. PubMed ID: 21270143
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Basal ganglia volumes in drug-naive first-episode schizophrenia patients before and after short-term treatment with either a typical or an atypical antipsychotic drug.
    Glenthoj A; Glenthoj BY; Mackeprang T; Pagsberg AK; Hemmingsen RP; Jernigan TL; Baaré WF
    Psychiatry Res; 2007 Apr; 154(3):199-208. PubMed ID: 17360162
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of long-acting risperidone on working memory in schizophrenia: a functional magnetic resonance imaging study.
    Surguladze SA; Chu EM; Evans A; Anilkumar AP; Patel MX; Timehin C; David AS
    J Clin Psychopharmacol; 2007 Dec; 27(6):560-70. PubMed ID: 18004121
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical experience and management considerations with long-acting risperidone.
    Parellada E
    Curr Med Res Opin; 2006 Feb; 22(2):241-55. PubMed ID: 16466596
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A 12-month, open-label, comparative study of quetiapine and risperidone in the acute and long-term treatment of schizophrenia.
    Perez V; Cañas F; Tafalla M;
    Int Clin Psychopharmacol; 2008 May; 23(3):138-49. PubMed ID: 18408528
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A cost-consequence analysis of long-acting injectable risperidone in schizophrenia: a one-year mirror-image study with national claim-based database in Taiwan.
    Chang HC; Tang CH; Huang ST; McCrone P; Su KP
    J Psychiatr Res; 2012 Jun; 46(6):751-6. PubMed ID: 22440883
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-Acting Injectable Risperidone for Relapse Prevention and Control of Breakthrough Symptoms After a Recent First Episode of Schizophrenia. A Randomized Clinical Trial.
    Subotnik KL; Casaus LR; Ventura J; Luo JS; Hellemann GS; Gretchen-Doorly D; Marder S; Nuechterlein KH
    JAMA Psychiatry; 2015 Aug; 72(8):822-9. PubMed ID: 26107752
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapeutic drug monitoring of patients on risperidone depot.
    Nesvåg R; Tanum L
    Nord J Psychiatry; 2005; 59(1):51-5. PubMed ID: 16195099
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risperidone long-acting injection in Schizophrenia Spectrum Illnesses compared to first generation depot antipsychotics in an outpatient setting in Canada.
    Lammers L; Zehm B; Williams R
    BMC Psychiatry; 2013 May; 13():155. PubMed ID: 23718192
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost effectiveness of long-acting risperidone in Sweden.
    Hensen M; Heeg B; Löthgren M; van Hout B
    Appl Health Econ Health Policy; 2010; 8(5):327-41. PubMed ID: 20804225
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of long-acting risperidone in psychiatric disorders: focus on efficacy, safety and cost-effectiveness.
    Keith S
    Expert Rev Neurother; 2009 Jan; 9(1):9-31. PubMed ID: 19102665
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.